Long-Term PF-06651600 for the Treatment of Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- Drug: PF-06651600Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccineBiological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Registration Number
- NCT04006457
- Lead Sponsor
- Pfizer
- Brief Summary
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1051
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment sequence 1 PF-06651600 Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study. Treatment sequence 1 Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study. Treatment sequence 2 PF-06651600 Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study. Treatment sequence 1 Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study. Treatment sequence 2 Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study. Treatment sequence 2 Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months. Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study.
- Primary Outcome Measures
Name Time Method Number of subjects reporting serious adverse events Baseline through Month 36 Number of subjects with clinically significant abnormalities in vital signs Baseline through Month 36 Number of subjects reporting treatment-emergent adverse events Baseline through Month 36 Number of subjects with clinically significant abnormalities in clinical laboratory values Baseline through Month 36 Vaccine sub-study: Percentage of subjects with a tetanus booster response Vaccine sub-study Month 1 Tetanus booster response is defined as 1) ≥4 fold rise in anti-tetanus toxoid IgG antibody concentration at Day 30 if the pre-vaccination concentration was ≤2.7 IU/mL; 2) ≥2 fold rise in anti tetanus toxoid IgG antibody if the pre-vaccination concentration was \>2.7 IU/mL
Number of subjects reporting adverse events leading to discontinuation Baseline through Month 36
- Secondary Outcome Measures
Name Time Method Percentage of subjects with an absolute Severity of Alopecia Tool (SALT) Score <=10 Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, and 36 SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
Change from baseline in SALT score Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, and 36 SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
Percentage of subjects with at least a 2 grade improvement or a score of 3 in Eyebrow Assessment (EBA) score Months 1, 3, 6, 12, 18, 24, and 36 EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal).
Change from baseline in the anxiety subscale score of the Hospital Anxiety and Depression Scale (HADS) Months 1, 3, 6, 9, 12, 18, 24, and 36 HADS is a participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety; HADS-D assesses state of lost interest and diminished pleasure response. Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Improvement on the Hospital Anxiety and Depression Scale (HADS) among participants with a baseline subscale score indicative of anxiety who achieved a "normal" subscale score indicative of an absence of anxiety Months 1, 3, 6, 9, 12, 18, 24, and 36 HADS is a participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety; HADS-D assesses state of lost interest and diminished pleasure response. Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Number of subjects with clinically significant abnormalities in vital signs Month 37 through Month 60 Number of subjects with clinically significant abnormalities in clinical laboratory values Month 37 through Month 60 Percentage of subjects with an absolute Severity of Alopecia Tool (SALT) Score <=20 Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, and 36 SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
Percentage of subjects with at least a 2 grade improvement or a score of 3 in Eyelash Assessment (ELA) score Months 1, 3, 6, 12, 18, 24, and 36 ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal).
Patient's Global Impression of Change (PGI-C) response, defined as PGI-C score of "moderately improved" or "greatly improved" Months 1, 3, 6, 9, 12, 18, 24, and 36 PGI-C is a self administered questionnaire evaluating improvement or worsening of the participant's alopecia areata as compared to the start of the study and uses a single item, "Since the start of the study, my alopecia areata has: ...", with 7 responses ranging from "greatly improved" to "greatly worsened."
Change from baseline in the depression subscale score of the Hospital Anxiety and Depression Scale (HADS) Months 1, 3, 6, 9, 12, 18, 24, and 36 HADS is a participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety; HADS-D assesses state of lost interest and diminished pleasure response. Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Improvement on the Hospital Anxiety and Depression Scale (HADS) among participants with a baseline subscale score indicative of depression who achieved a "normal" subscale score indicative of an absence of depression Months 1, 3, 6, 9, 12, 18, 24, and 36 HADS is a participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety; HADS-D assesses state of lost interest and diminished pleasure response. Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Vaccine sub-study: Percentage of subjects with anti-tetanus antibody level ≥0.1 IU/mL Vaccine sub-study Month 1 Vaccine sub-study: Percentage of subjects with ≥4x increase in anti-tetanus antibody level from baseline Vaccine sub-study Month 1 Percentage of subjects with a 75% improvement in SALT score from baseline Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, and 36 SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
Change from baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) domains Months 1, 3, 6, 9, 12, 18, 24, and 36 The AAPPO scale is a self administered questionnaire that measures the symptoms of AA as well as psychological and functional impacts over the past week.
Vaccine sub-study: Geometric mean concentrations (GMCs) of anti-tetanus antibody levels Vaccine sub-study Month 1 Vaccine sub-study: Number of subjects reporting adverse events leading to discontinuation Vaccine sub-study Month 1 Vaccine sub-study: Percentage of subjects with a meningococcal serogroup C response Vaccine sub-study Month 1 Meningococcal serogroup C response is defined as achieving ≥1:8 human serum bactericidal activity (hSBA) (in participants with undetectable pre-vaccination assay titers)
Vaccine sub-study: Percentage of subjects with anti-tetanus antibody level ≥1.0 IU/mL Vaccine sub-study Month 1 Vaccine sub-study: Fold increase in anti-tetanus levels above baseline values Vaccine sub-study Month 1 Vaccine sub-study: Percentage of subjects with ≥1:4 hSBA (in subjects with undetectable pre-vaccination assay titers) for meningococcal serogroup C Vaccine sub-study Month 1 Vaccine sub-study: Geometric mean titers (GMTs) of antibodies for meningococcal serogroup C Vaccine sub-study Day 1 and Month 1 Number of subjects reporting adverse events leading to discontinuation Month 37 through Month 60 Vaccine sub-study: Number of subjects reporting serious adverse events Vaccine sub-study Month 1 Vaccine sub-study: Number of subjects reporting adverse events Vaccine sub-study Month 1 Number of subjects reporting treatment-emergent adverse events Month 37 through Month 60 Number of subjects reporting serious adverse events Month 37 through Month 60
Trial Locations
- Locations (156)
FSBEI HE Russian University of Medicine of the MoH of Russia
🇷🇺Moscow, Russian Federation
The University of Alabama at Birmingham Hosptial Outreach Lab
🇺🇸Birmingham, Alabama, United States
The University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
The University of Alabama at Birmingham, Department of Dermatology
🇺🇸Birmingham, Alabama, United States
Mosaic Dermatology
🇺🇸Beverly Hills, California, United States
Univ of California, Irvine, Dermatology Clinical Research Center
🇺🇸Irvine, California, United States
Dermatology Specialists Inc.
🇺🇸Murrieta, California, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
Kaiser Permanente Clinical Trials Unit
🇺🇸San Francisco, California, United States
Southern California Dermatology, Inc.
🇺🇸Santa Ana, California, United States
University of Colorado Anschutz Medical Campus
🇺🇸Aurora, Colorado, United States
University of Colorado Hospital Clinical and Translational Research Center
🇺🇸Aurora, Colorado, United States
University of Colorado Hospital Outpatient Pavilion
🇺🇸Aurora, Colorado, United States
Yale School of Medicine
🇺🇸New Haven, Connecticut, United States
Investigational Drug Services
🇺🇸New Haven, Connecticut, United States
Yale School of Medicine, Yale Center for Clinical Investigations
🇺🇸New Haven, Connecticut, United States
Yale School of Medicine, Yale Center for Clinical Investigation
🇺🇸New Haven, Connecticut, United States
Medstar Georgetown University Hospital - Department of Otolaryngology
🇺🇸Washington, District of Columbia, United States
Medstar Georgetown University Hospital-Dept of Otolaryngology
🇺🇸Washington, District of Columbia, United States
Medstar Washington Hospital Center-Claude Nogay Research Pharmacy
🇺🇸Washington, District of Columbia, United States
MedStar Washington Hospital Center
🇺🇸Washington, District of Columbia, United States
Medstar Georgetown University Hospital - Department of Pediatrics
🇺🇸Washington, District of Columbia, United States
Siperstein Dermatology Group
🇺🇸Boynton Beach, Florida, United States
Park Avenue Dermatology
🇺🇸Orange Park, Florida, United States
ForCare Clinical Research
🇺🇸Tampa, Florida, United States
Velocity Clinical Research - Boise
🇺🇸Meridian, Idaho, United States
Northwestern Medical Group
🇺🇸Chicago, Illinois, United States
Northwestern Medicine Diagnostic Testing Center
🇺🇸Chicago, Illinois, United States
Northwestern Medicine
🇺🇸Chicago, Illinois, United States
Northwestern Memorial Hospital Investigational Drug Service Pharmacy
🇺🇸Chicago, Illinois, United States
Northwestern Memorial Hospital
🇺🇸Chicago, Illinois, United States
Summit Dermatology and Aesthetic Surgery (in c/o TrialSpark, Inc)
🇺🇸Oakbrook Terrace, Illinois, United States
NorthShore University HealthSystem Dermatology Clinical Trials Unit
🇺🇸Skokie, Illinois, United States
Northshore University HealthSystem/Dermatology
🇺🇸Skokie, Illinois, United States
Southern Illinois University School of Medicine
🇺🇸Springfield, Illinois, United States
Dawes Fretzin Clinical Research Group, LLC
🇺🇸Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Medstar Georgetown University Hospital - Department of Dermatology
🇺🇸Chevy Chase, Maryland, United States
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
🇺🇸Boston, Massachusetts, United States
University of Minnesota Clinical Research Unit (CRU)
🇺🇸Minneapolis, Minnesota, United States
University of Minnesota Lillehei Clinical Research Unit (LCRU)
🇺🇸Minneapolis, Minnesota, United States
University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke
🇺🇸Minneapolis, Minnesota, United States
Skin Specialists, PC (Schlessinger MD)
🇺🇸Omaha, Nebraska, United States
Skin Specialists PC
🇺🇸Omaha, Nebraska, United States
Schweiger Dermatology, P.C.
🇺🇸Verona, New Jersey, United States
NYU School of Medicine, The Ronald O. Perelman Department of Dermatology
🇺🇸New York, New York, United States
Pura Dermatology (in c/o TrialSpark, Inc)
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
UNC Hospitals, Investigational Drug Service
🇺🇸Chapel Hill, North Carolina, United States
UNC CTRC
🇺🇸Chapel Hill, North Carolina, United States
UNC Dermatology and Skin Cancer Center
🇺🇸Chapel Hill, North Carolina, United States
UNC Dermatology Clinical Trials Unit
🇺🇸Chapel Hill, North Carolina, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Vital Prospects Clinical Research Institute, P.C.
🇺🇸Tulsa, Oklahoma, United States
Oregon Medical Research Center
🇺🇸Portland, Oregon, United States
The University of Texas Health Science Center at Houston
🇺🇸Bellaire, Texas, United States
Tamjidi Skin Institute (in c/o TrialSpark, Inc)
🇺🇸Vienna, Virginia, United States
CINME Centro de Investigaciones Metabolicas
🇦🇷Caba, Buenos Aires, Argentina
Psoriahue Medicina Interdisciplinaria
🇦🇷Caba, Argentina
Premier Specialists Pty Ltd
🇦🇺Kogarah, New South Wales, Australia
St George Dermatology & Skin Cancer Centre
🇦🇺Kogarah, New South Wales, Australia
The Skin Centre
🇦🇺Benowa, Queensland, Australia
Veracity Clinical Research Pty Ltd
🇦🇺Woolloongabba, Queensland, Australia
Skin Health Institute
🇦🇺Carlton, Victoria, Australia
Sinclair Dermatology
🇦🇺East Melbourne, Victoria, Australia
Royal Melbourne Hospital, Melbourne Health
🇦🇺Parkville, Victoria, Australia
Royal Melbourne Hospital
🇦🇺Parkville, Victoria, Australia
Wiseman Dermatology Research Inc.
🇨🇦Winnipeg, Manitoba, Canada
Eastern Canada Cutaneous Research Associates Ltd.
🇨🇦Halifax, Nova Scotia, Canada
Guenther Research Inc
🇨🇦London, Ontario, Canada
Lynderm Research Inc.
🇨🇦Markham, Ontario, Canada
The Centre for Clinical Trials
🇨🇦Oakville, Ontario, Canada
SKiN Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
York Dermatology Clinic and Research Centre
🇨🇦Richmond Hill, Ontario, Canada
Medicor Research Inc
🇨🇦Sudbury, Ontario, Canada
Sudbury Skin Clinique
🇨🇦Sudbury, Ontario, Canada
Research Toronto
🇨🇦Toronto, Ontario, Canada
Innovaderm Research Inc.
🇨🇦Montreal, Quebec, Canada
Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
🇨🇦Quebec, Canada
Centro Medico Skin Med
🇨🇱Santiago, LAS Condes, Chile
Centro Internacional de Estudios Clinicos - CIEC
🇨🇱Santiago, Recoleta, Chile
Medical Skin Center
🇨🇱Vina del Mar, Valparaiso, Chile
Clinica Dermacross S.A.
🇨🇱Santiago, Vitacura, Chile
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
The University of Hong Kong - Shenzhen Hospital
🇨🇳Shenzhen, Guangdong, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The First Affiliated Hospital with Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Fundacion Centro de Investigacion Clinica CIC
🇨🇴Medellin, Antioquia, Colombia
Fundacion Hospitalaria San Vicente de Paul
🇨🇴Medellin, Antioquia, Colombia
Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S
🇨🇴Bogota D.C., Colombia
DERMAMEDICA s.r.o.
🇨🇿Nachod, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Clintrial s.r.o.
🇨🇿Praha 10, Czechia
Sanatorium profesora Arenbergera
🇨🇿Praha 1, Czechia
Fachklinik Bad Bentheim
🇩🇪Bad Bentheim, Germany
Emovis GmbH
🇩🇪Berlin, Germany
Universitaetsklinikum Erlangen
🇩🇪Erlangen, Germany
University Hospital Frankfurt
🇩🇪Frankfurt am Main, Germany
University Hospital Schleswig-Holstein
🇩🇪Luebeck, Germany
University Hospital Muenster
🇩🇪Muenster, Germany
Nagoya City University Hospital
🇯🇵Nagoya, Aichi, Japan
Tohoku University Hospital
🇯🇵Sendai, Miyagi, Japan
Hamamatsu University Hospital
🇯🇵Hamamatsu, Shizuoka, Japan
Juntendo Tokyo Koto Geriatric Medical Center
🇯🇵Koto-ku, Tokyo, Japan
Kyorin University Hospital
🇯🇵Mitaka-shi, Tokyo, Japan
Osaka Metropolitan University Hospital
🇯🇵Osaka, Japan
Tokyo Medical University Hospital
🇯🇵Tokyo, Japan
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Sociedad de Metabolismo y Corazon S.C.
🇲🇽Veracruz, Mexico
Hospital D Maria
🇲🇽Veracruz, Mexico
Twoja Przychodnia SCM
🇵🇱Szczecin, Zachodniopomorskie, Poland
McBk S.C.
🇵🇱Grodzisk Mazowiecki, Poland
Centermed Krakow Sp.z o.o.
🇵🇱Krakow, Poland
Dermoklinika Centrum Medyczne s.c. M.Kierstan, J. Narbutt, A. Lesiak
🇵🇱Lodz, Poland
Dermedic Jacek Zdybski
🇵🇱Ostrowiec Swietokrzyski, Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne
🇵🇱Szczecin, Poland
RCMed Oddzial Warszawa
🇵🇱Warszawa, Poland
Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
🇵🇱Warszawa, Poland
ETG Warszawa
🇵🇱Warszawa, Poland
Royalderm Agnieszka Nawrocka
🇵🇱Warszawa, Poland
EMC Instytut Medyczny S.A. Przychodnia przy ul. Lowieckiej we Wroclawiu
🇵🇱Wroclaw, Poland
Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
🇵🇱Wroclaw, Poland
Centrum Medyczne OPOROW
🇵🇱Wroclaw, Poland
State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical Dermatovenerologic Dispensary"
🇷🇺Chelyabinsk, Russian Federation
University Clinic of Kirov SMU
🇷🇺Kirov, Russian Federation
Clinical Medical Center of Moscow State University of Medicine and Dentistry
🇷🇺Moscow, Russian Federation
Federal State Autonomous Institution "National Medical Research Centre of Children's' Health"
🇷🇺Moscow, Russian Federation
State Budgetary Institution of the Rostov Region "Dermatovenerologic Dispensary"
🇷🇺Rostov-on-Don, Russian Federation
Limited Liability Company "Pierre Volkenshtein Skin Diseases Clinic"
🇷🇺Saint Petersburg,, Russian Federation
Limited Liability Company "Centre Vitiligo" ("Centre Vitiligo" LLC)
🇷🇺Saint Petersburg, Russian Federation
Saint Petersburg State Budgetary Healthcare Institution "Dermatovenerologic Dispensary No. 10 -
🇷🇺Saint Petersburg, Russian Federation
State Autonomous Healthcare Institution of the Yaroslavl Region "Clinical Emergency Hospital
🇷🇺Yaroslavl, Russian Federation
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Hospital Universitario Infanta Leonor
🇪🇸Madrid, Spain
Hospital Universitario La Paz: Servicio de Farmacia
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario y Politecnico La Fe
🇪🇸Valencia, Spain
Chung-Shan Medical University Hospital
🇨🇳Taichung, R.o.c., Taiwan
Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare
🇨🇳New Taipei City, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan City, Taiwan
University Hospital Southampton NHS Foundation Trust
🇬🇧Southampton, Hampshire, United Kingdom
University Hospitals Sussex NHS Foundation Trust (UHSussex)
🇬🇧Brighton, United Kingdom
Guy's and St Thomas Hospitals NHS Foundation Trust, St Thomas Hospital
🇬🇧London, United Kingdom
NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital
🇬🇧Glasgow, United Kingdom
Guy's and St Thomas' Hospitals NHS Foundation Trust, St Thomas' Hospital
🇬🇧London, United Kingdom
Guy's and St Thomas' Hospitals NHS Foundation Trust, Guy's Hospital
🇬🇧London, United Kingdom